Mechanism of Action of a Novel Human ether-a-go-go-Related Gene Channel Activator

1,3-Bis-(2-hydroxy-5-trifluoromethyl-phenyl)-urea (NS1643) is a newly discovered activator of human ether-a-go-go-related gene (hERG) K+ channels. Here, we characterize the effects of this compound on cloned hERG channels heterologously expressed in Xenopus laevis oocytes. When assessed with 2-s depolarizations, NS1643 enhanced the magnitude of wild-type hERG current in a concentration- and voltage-dependent manner with an EC50 of 10.4 μM at –10 mV. The fully activated current-voltage relationship revealed that the drug increased outward but not inward currents, consistent with altered inactivation gating. NS1643 shifted the voltage dependence of inactivation by +21 mV at 10 μM and +35 mV at 30 μM, but it did not alter the voltage dependence of activation of hERG channels. The effects of the drug on three inactivation-deficient hERG mutant channels (S620T, S631A, and G628C/S631C) were determined. In the absence of channel inactivation, NS1643 did not enhance hERG current magnitude. The agonist activity of NS1643 was facilitated by mutations (F656 to Val, Met, or Thr) that are known to greatly attenuate channel inhibition by hERG blockers. We conclude that NS1643 is a partial agonist of hERG channels and that the mechanism of activation is reduced channel inactivation.

[1]  Michael C Sanguinetti,et al.  Voltage-dependent profile of human ether-a-go-go-related gene channel block is influenced by a single residue in the S6 transmembrane domain. , 2003, Molecular pharmacology.

[2]  W. Stühmer,et al.  Electrophysiological recording from Xenopus oocytes. , 1992, Methods in enzymology.

[3]  M. Sanguinetti,et al.  A novel benzodiazepine that activates cardiac slow delayed rectifier K+ currents. , 1998, Molecular pharmacology.

[4]  M. Sanguinetti,et al.  Fast inactivation causes rectification of the IKr channel , 1996, The Journal of general physiology.

[5]  G. Breithardt,et al.  Life-threatening Arrhythmias Genotype-phenotype Correlation in the Long-qt Syndrome : Gene-specific Triggers for Genotype-phenotype Correlation in the Long-qt Syndrome Gene-specific Triggers for Life-threatening Arrhythmias , 2022 .

[6]  Robert Pearlstein,et al.  Understanding the structure-activity relationship of the human ether-a-go-go-related gene cardiac K+ channel. A model for bad behavior. , 2003, Journal of medicinal chemistry.

[7]  S. Priori,et al.  The long QT syndrome. , 1997, Current problems in cardiology.

[8]  Jiesheng Kang,et al.  Discovery of a Small Molecule Activator of the Human Ether-a-go-go-Related Gene (HERG) Cardiac K+ Channel , 2005, Molecular Pharmacology.

[9]  Gregory W. Kauffman,et al.  Physicochemical Features of the hERG Channel Drug Binding Site* , 2004, Journal of Biological Chemistry.

[10]  G. Robertson,et al.  HERG, a human inward rectifier in the voltage-gated potassium channel family. , 1995, Science.

[11]  Michael C Sanguinetti,et al.  Molecular Determinants of Voltage-dependent Human Ether-a-Go-Go Related Gene (HERG) K+ Channel Block* , 2002, The Journal of Biological Chemistry.

[12]  Bertram Pitt,et al.  Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction , 1996, The Lancet.

[13]  Robert F Gilmour,et al.  Suppression of electrical alternans by overexpression of HERG in canine ventricular myocytes. , 2004, American journal of physiology. Heart and circulatory physiology.

[14]  M. Sanguinetti,et al.  A structural basis for drug-induced long QT syndrome. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[15]  K. Lawson,et al.  Potassium channel openers as potential therapeutic weapons in ion channel disease. , 2000, Kidney international.

[16]  Jun Zhou,et al.  Novel Potent Human Ether-à-Go-Go-Related Gene (hERG) Potassium Channel Enhancers and Their in Vitro Antiarrhythmic Activity , 2005, Molecular Pharmacology.

[17]  M. Sanguinetti,et al.  A mutation in the pore region of HERG K+ channels expressed in Xenopus oocytes reduces rectification by shifting the voltage dependence of inactivation , 1998, The Journal of physiology.

[18]  Y. P. Adams,et al.  MECHANISMS AND MANAGEMENT , 1998 .

[19]  M. Sanguinetti,et al.  A mechanistic link between an inherited and an acquird cardiac arrthytmia: HERG encodes the IKr potassium channel , 1995, Cell.

[20]  G. Sarkar,et al.  The "megaprimer" method of site-directed mutagenesis. , 1990, BioTechniques.

[21]  H. Duff,et al.  Molecular determinant of high-affinity dofetilide binding to HERG1 expressed in Xenopus oocytes: involvement of S6 sites. , 2000, Molecular pharmacology.

[22]  C Antzelevitch,et al.  The potential for QT prolongation and proarrhythmia by non-antiarrhythmic drugs: clinical and regulatory implications. Report on a policy conference of the European Society of Cardiology. , 2000, European heart journal.

[23]  M. Sanguinetti,et al.  Block of wild-type and inactivation-deficient human ether-a-go-go-related gene K+ channels by halofantrine , 2004, Naunyn-Schmiedeberg's Archives of Pharmacology.

[24]  A. Keren,et al.  Magnesium therapy for torsades de pointes. , 1984, The American journal of cardiology.

[25]  P. Schraeder,et al.  Stress and sudden death , 2006, Epilepsy & Behavior.

[26]  R. Martínez,et al.  Torsades de pointes: atypical rhythm, atypical treatment. , 1987, Annals of emergency medicine.

[27]  Robert F Gilmour,et al.  Contribution of IKr to Rate-Dependent Action Potential Dynamics in Canine Endocardium , 2004, Circulation research.

[28]  M. Sanguinetti,et al.  Molecular and Cellular Mechanisms of Cardiac Arrhythmias , 2001, Cell.

[29]  A. Moss,et al.  Stress and sudden death. The case of the long QT syndrome. , 1991, Circulation.

[30]  M. Sanguinetti,et al.  Pharmacological Activation of Normal and Arrhythmia-Associated Mutant KCNQ1 Potassium Channels , 2003, Circulation research.

[31]  U. Ravens,et al.  Activation of Human ether-a-go-go-Related Gene Potassium Channels by the Diphenylurea 1,3-Bis-(2-hydroxy-5-trifluoromethyl-phenyl)-urea (NS1643) , 2006, Molecular Pharmacology.

[32]  A. Camm,et al.  The potential for QT prolongation and pro-arrhythmia by non-anti-arrhythmic drugs: clinical and regulatory implications. Report on a Policy Conference of the European Society of Cardiology. , 2000, Cardiovascular research.

[33]  P. Schwartz,et al.  Torsade de pointes. Mechanisms and management. , 1994, Drugs.

[34]  Gary Yellen,et al.  The inward rectification mechanism of the HERG cardiac potassium channel , 1996, Nature.